OSE Immunotherapeutics SA (EPA:OSE)

France flag France · Delayed Price · Currency is EUR
5.88
-0.11 (-1.75%)
Sep 26, 2025, 5:35 PM CET
-25.38%
Market Cap 135.05M
Revenue (ttm) 83.44M
Net Income (ttm) 37.45M
Shares Out 22.97M
EPS (ttm) 1.46
PE Ratio 4.03
Forward PE 6.50
Dividend n/a
Ex-Dividend Date n/a
Volume 159,949
Average Volume 80,520
Open 5.95
Previous Close 5.99
Day's Range 5.61 - 5.99
52-Week Range 4.42 - 11.58
Beta 0.45
RSI 47.25
Earnings Date Sep 26, 2025

About OSE Immunotherapeutics

OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. Its products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 64
Stock Exchange Euronext Paris
Ticker Symbol OSE
Full Company Profile

Financial Performance

Financial Statements

News

OSE Immunotherapeutics SA (ORPOF) Shareholder/Analyst Call Transcript

OSE Immunotherapeutics SA (OTC:ORPOF) Shareholder/Analyst Call September 18, 2025 12:00 PM EDTCompany ParticipantsFiona Olivier - Chief Corporate Affairs...

10 days ago - Seeking Alpha